Monthly
US$200
Billed every month
Folic Acid Tablets(叶酸片)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 3 applicationsNo longer listed under review: 1 applicationSupplement delivery: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders10View records ↓
Under-review filings12View records ↓
This year’s generic filers3View records ↓
NHSA approval numbers41View records ↓
API companies with A status8View records ↓
Chemical-drug catalogue
Loaded records: 10 holders; 5 in the quality-and-efficacy consistency-evaluation category, and 5 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 江苏联环药业股份有限公司 | 江苏联环药业股份有限公司 | 国药准字H20044918 | 2026/06/16 | 5mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 南京泽恒医药技术开发有限公司 | 江苏神龙药业有限公司 | 国药准字H20264140 | 2026/04/29 | 5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华北制药股份有限公司 | 华北制药股份有限公司 | 国药准字H13020800 | 2025/02/22 | 5mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 浙江诺得药业有限公司 | 浙江诺得药业有限公司 | 国药准字H20244242 | 2024/06/28 | 5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 森淼（山东）药业有限公司 | 济南永宁制药股份有限公司 | 国药准字H20243422 | 2024/03/29 | 5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 河北冀衡药业股份有限公司 | 河北冀衡药业股份有限公司 | 国药准字H20234494 | 2023/11/21 | 5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江佰奥医药科技有限公司 | 浙江北生药业汉生制药有限公司 | 国药准字H20234272 | 2023/10/12 | 5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天津力生制药股份有限公司 | 天津力生制药股份有限公司 | 国药准字H12020215 | 2022/09/05 | 5mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 常州制药厂有限公司 | 常州制药厂有限公司 | 国药准字H32023302 | 2022/07/22 | 5mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 西安利君制药有限责任公司 | 西安利君制药有限责任公司 | 国药准字H61022396 | 2022/07/22 | 5mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 41 distinct approval numbers and 35 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京斯利安药业有限公司 | 国药准字H10970079 | 0.4mg | Category A (甲) | XB03BBY050A001010100011 | NHSA |
| 北京麦迪海药业有限责任公司 | 国药准字H11020317 | 0.4mg | Category A (甲) | XB03BBY050A001010100096 | NHSA |
| 华润紫竹药业有限公司 | 国药准字H20183478 | 0.4mg | Category A (甲) | XB03BBY050A001010100225 | NHSA |
| 广东彼迪药业有限公司 | 国药准字H44021625 | 5mg | Category A (甲) | XB03BBY050A001010100269 | NHSA |
| 三才制药(中山)股份有限公司 | 国药准字H44023240 | 5mg | Category A (甲) | XB03BBY050A001010100322 | NHSA |
| 广州白云山光华制药股份有限公司 | 国药准字H44020019 | 5mg | Category A (甲) | XB03BBY050A001010100372 | NHSA |
| 上海新黄河制药有限公司 | 国药准字H31020147 | 5mg | Category A (甲) | XB03BBY050A001010100787 | NHSA |
| 秦皇岛爱晖药业有限公司 | 国药准字H20067437 | 0.4mg | Category A (甲) | XB03BBY050A001010100858 | NHSA |
| 天津力生制药股份有限公司 | 国药准字H20059355 | 0.4mg | Category A (甲) | XB03BBY050A001010100886 | NHSA |
| 天津儿童药业有限公司 | 国药准字H20093919 | 0.4mg | Category A (甲) | XB03BBY050A001010100900 | NHSA |
| 原研药港生物制药(沈阳)股份有限公司 | 国药准字H21021044 | 0.4mg | Category A (甲) | XB03BBY050A001010101304 | NHSA |
| 常州制药厂有限公司 | 国药准字H20003143 | 0.4mg | Category A (甲) | XB03BBY050A001010101397 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20044917 | 0.4mg | Category A (甲) | XB03BBY050A001010101467 | NHSA |
| 江苏亚邦爱普森药业有限公司 | 国药准字H32023288 | 5mg | Category A (甲) | XB03BBY050A001010101510 | NHSA |
| 正大天晴药业集团股份有限公司 | 国药准字H32022919 | 5mg | Category A (甲) | XB03BBY050A001010101523 | NHSA |
| 陕西新沣华生物科技有限公司 | 国药准字H61022396 | 5mg | Category A (甲) | XB03BBY050A001010102503 | NHSA |
| 河北冀衡药业股份有限公司 | 国药准字H20234494 | 5mg | Category A (甲) | XB03BBY050A001010102625 | NHSA |
| 华北制药股份有限公司 | 国药准字H20143386 | 0.4mg | Category A (甲) | XB03BBY050A001010102690 | NHSA |
| 华北制药股份有限公司 | 国药准字H13020800 | 5mg | Category A (甲) | XB03BBY050A001010102699 | NHSA |
| 河北爱普制药有限公司 | 国药准字H20263489 | 5mg | Category A (甲) | XB03BBY050A001010102756 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H13022877 | 5mg | Category A (甲) | XB03BBY050A001010102770 | NHSA |
| 济南永宁制药股份有限公司 | 国药准字H37022543 | 5mg | Category A (甲) | XB03BBY050A001010103987 | NHSA |
| 烟台中洲制药有限公司 | 国药准字H20093829 | 0.4mg | Category A (甲) | XB03BBY050A001010104253 | NHSA |
| 杭州澳医保灵药业有限公司 | 国药准字H20123159 | 0.4mg | Category A (甲) | XB03BBY050A001010104471 | NHSA |
| 福州海王福药制药有限公司 | 国药准字H35020215 | 5mg | Category A (甲) | XB03BBY050A001010104827 | NHSA |
| 国药控股星鲨制药(厦门)有限公司 | 国药准字H35020894 | 5mg | Category A (甲) | XB03BBY050A001010104873 | NHSA |
| 江西制药有限责任公司 | 国药准字H36020872 | 0.4毫克 | Category A (甲) | XB03BBY050A001010105388 | NHSA |
| 甘肃兰药药业有限公司 | 国药准字H62020684 | 5mg | Category A (甲) | XB03BBY050A001010105863 | NHSA |
| 沈阳天邦药业有限公司 | 国药准字H20254768 | 5mg | Category A (甲) | XB03BBY050A001010110021 | NHSA |
| 山东鑫惠药业有限公司 | 国药准字H20194058 | 0.4mg | Category A (甲) | XB03BBY050A001010180465 | NHSA |
| 南京泽恒医药技术开发有限公司 | 国药准字H20264140 | 5mg | Category A (甲) | XB03BBY050A001010183339 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001010183521 | NHSA |
| 森淼(山东)药业有限公司 | 国药准字H20243422 | 5mg | Category A (甲) | XB03BBY050A001010184029 | NHSA |
| 浙江佰奥医药科技有限公司 | 国药准字H20234272 | 5mg | Category A (甲) | XB03BBY050A001010184220 | NHSA |
| 北京斯利安药业有限公司 | 国药准字H10970079 | 0.4mg | Category A (甲) | XB03BBY050A001010200011 | NHSA |
| 北京麦迪海药业有限责任公司 | 国药准字H11020317 | 0.4mg | Category A (甲) | XB03BBY050A001010200096 | NHSA |
| 三才制药(中山)股份有限公司 | 国药准字H44023240 | 5mg | Category A (甲) | XB03BBY050A001010200322 | NHSA |
| 秦皇岛爱晖药业有限公司 | 国药准字H20067437 | 0.4mg | Category A (甲) | XB03BBY050A001010200858 | NHSA |
| 天津力生制药股份有限公司 | 国药准字H20059355 | 0.4mg | Category A (甲) | XB03BBY050A001010200886 | NHSA |
| 天津儿童药业有限公司 | 国药准字H20093919 | 0.4mg | Category A (甲) | XB03BBY050A001010200900 | NHSA |
| 原研药港生物制药(沈阳)股份有限公司 | 国药准字H21021044 | 0.4mg | Category A (甲) | XB03BBY050A001010201304 | NHSA |
| 常州制药厂有限公司 | 国药准字H20003143 | 0.4mg | Category A (甲) | XB03BBY050A001010201397 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20044917 | 0.4mg | Category A (甲) | XB03BBY050A001010201467 | NHSA |
| 陕西新沣华生物科技有限公司 | 国药准字H61022396 | 5mg | Category A (甲) | XB03BBY050A001010202503 | NHSA |
| 华北制药股份有限公司 | 国药准字H20143386 | 0.4mg | Category A (甲) | XB03BBY050A001010202690 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H13022877 | 5mg | Category A (甲) | XB03BBY050A001010202770 | NHSA |
| 山东明仁福瑞达制药股份有限公司 | 国药准字H37022088 | 5mg | Category A (甲) | XB03BBY050A001010203965 | NHSA |
| 烟台中洲制药有限公司 | 国药准字H20093829 | 0.4mg | Category A (甲) | XB03BBY050A001010204253 | NHSA |
| 福州海王福药制药有限公司 | 国药准字H35020215 | 5mg | Category A (甲) | XB03BBY050A001010204827 | NHSA |
| 江西制药有限责任公司 | 国药准字H36020872 | 0.4毫克 | Category A (甲) | XB03BBY050A001010205388 | NHSA |
| 山东鑫惠药业有限公司 | 国药准字H20194058 | 0.4mg | Category A (甲) | XB03BBY050A001010280465 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001010283521 | NHSA |
| 森淼(山东)药业有限公司 | 国药准字H20243422 | 5mg | Category A (甲) | XB03BBY050A001010284029 | NHSA |
| 浙江佰奥医药科技有限公司 | 国药准字H20234272 | 5mg | Category A (甲) | XB03BBY050A001010284220 | NHSA |
| 北京斯利安药业有限公司 | 国药准字H10970079 | 0.4mg | Category A (甲) | XB03BBY050A001010300011 | NHSA |
| 北京麦迪海药业有限责任公司 | 国药准字H11020317 | 0.4mg | Category A (甲) | XB03BBY050A001010300096 | NHSA |
| 天津力生制药股份有限公司 | 国药准字H20059355 | 0.4mg | Category A (甲) | XB03BBY050A001010300886 | NHSA |
| 天津儿童药业有限公司 | 国药准字H20093919 | 0.4mg | Category A (甲) | XB03BBY050A001010300900 | NHSA |
| 原研药港生物制药(沈阳)股份有限公司 | 国药准字H21021044 | 0.4mg | Category A (甲) | XB03BBY050A001010301304 | NHSA |
| 常州制药厂有限公司 | 国药准字H20003143 | 0.4mg | Category A (甲) | XB03BBY050A001010301397 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20044917 | 0.4mg | Category A (甲) | XB03BBY050A001010301467 | NHSA |
| 陕西新沣华生物科技有限公司 | 国药准字H61022396 | 5mg | Category A (甲) | XB03BBY050A001010302503 | NHSA |
| 烟台中洲制药有限公司 | 国药准字H20093829 | 0.4mg | Category A (甲) | XB03BBY050A001010304253 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19993229 | 0.4mg | Category A (甲) | XB03BBY050A001010304781 | NHSA |
| 江西制药有限责任公司 | 国药准字H36020872 | 0.4毫克 | Category A (甲) | XB03BBY050A001010305388 | NHSA |
| 山东鑫惠药业有限公司 | 国药准字H20194058 | 0.4mg | Category A (甲) | XB03BBY050A001010380465 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001010383521 | NHSA |
| 森淼(山东)药业有限公司 | 国药准字H20243422 | 5mg | Category A (甲) | XB03BBY050A001010384029 | NHSA |
| 浙江佰奥医药科技有限公司 | 国药准字H20234272 | 5mg | Category A (甲) | XB03BBY050A001010384220 | NHSA |
| 北京斯利安药业有限公司 | 国药准字H10970079 | 0.4mg | Category A (甲) | XB03BBY050A001010400011 | NHSA |
| 北京麦迪海药业有限责任公司 | 国药准字H11020317 | 0.4mg | Category A (甲) | XB03BBY050A001010400096 | NHSA |
| 天津力生制药股份有限公司 | 国药准字H20059355 | 0.4mg | Category A (甲) | XB03BBY050A001010400886 | NHSA |
| 天津儿童药业有限公司 | 国药准字H20093919 | 0.4mg | Category A (甲) | XB03BBY050A001010400900 | NHSA |
| 原研药港生物制药(沈阳)股份有限公司 | 国药准字H21021044 | 0.4mg | Category A (甲) | XB03BBY050A001010401304 | NHSA |
| 常州制药厂有限公司 | 国药准字H20003143 | 0.4mg | Category A (甲) | XB03BBY050A001010401397 | NHSA |
| 陕西新沣华生物科技有限公司 | 国药准字H61022396 | 5mg | Category A (甲) | XB03BBY050A001010402503 | NHSA |
| 烟台中洲制药有限公司 | 国药准字H20093829 | 0.4mg | Category A (甲) | XB03BBY050A001010404253 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19993229 | 0.4mg | Category A (甲) | XB03BBY050A001010404781 | NHSA |
| 江西制药有限责任公司 | 国药准字H36020872 | 0.4毫克 | Category A (甲) | XB03BBY050A001010405388 | NHSA |
| 山东鑫惠药业有限公司 | 国药准字H20194058 | 0.4mg | Category A (甲) | XB03BBY050A001010480465 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001010483521 | NHSA |
| 北京斯利安药业有限公司 | 国药准字H10970079 | 0.4mg | Category A (甲) | XB03BBY050A001010500011 | NHSA |
| 天津力生制药股份有限公司 | 国药准字H20059355 | 0.4mg | Category A (甲) | XB03BBY050A001010500886 | NHSA |
| 天津儿童药业有限公司 | 国药准字H20093919 | 0.4mg | Category A (甲) | XB03BBY050A001010500900 | NHSA |
| 原研药港生物制药(沈阳)股份有限公司 | 国药准字H21021044 | 0.4mg | Category A (甲) | XB03BBY050A001010501304 | NHSA |
| 常州制药厂有限公司 | 国药准字H20003143 | 0.4mg | Category A (甲) | XB03BBY050A001010501397 | NHSA |
| 陕西新沣华生物科技有限公司 | 国药准字H61022396 | 5mg | Category A (甲) | XB03BBY050A001010502503 | NHSA |
| 烟台中洲制药有限公司 | 国药准字H20093829 | 0.4mg | Category A (甲) | XB03BBY050A001010504253 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19993229 | 0.4mg | Category A (甲) | XB03BBY050A001010504781 | NHSA |
| 山东鑫惠药业有限公司 | 国药准字H20194058 | 0.4mg | Category A (甲) | XB03BBY050A001010580465 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001010583521 | NHSA |
| 北京斯利安药业有限公司 | 国药准字H10970079 | 0.4mg | Category A (甲) | XB03BBY050A001010600011 | NHSA |
| 天津儿童药业有限公司 | 国药准字H20093919 | 0.4mg | Category A (甲) | XB03BBY050A001010600900 | NHSA |
| 原研药港生物制药(沈阳)股份有限公司 | 国药准字H21021044 | 0.4mg | Category A (甲) | XB03BBY050A001010601304 | NHSA |
| 常州制药厂有限公司 | 国药准字H20003143 | 0.4mg | Category A (甲) | XB03BBY050A001010601397 | NHSA |
| 烟台中洲制药有限公司 | 国药准字H20093829 | 0.4mg | Category A (甲) | XB03BBY050A001010604253 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19993229 | 0.4mg | Category A (甲) | XB03BBY050A001010604781 | NHSA |
| 山东鑫惠药业有限公司 | 国药准字H20194058 | 0.4mg | Category A (甲) | XB03BBY050A001010680465 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001010683521 | NHSA |
| 北京斯利安药业有限公司 | 国药准字H10970079 | 0.4mg | Category A (甲) | XB03BBY050A001010700011 | NHSA |
| 天津儿童药业有限公司 | 国药准字H20093919 | 0.4mg | Category A (甲) | XB03BBY050A001010700900 | NHSA |
| 烟台中洲制药有限公司 | 国药准字H20093829 | 0.4mg | Category A (甲) | XB03BBY050A001010704253 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19993229 | 0.4mg | Category A (甲) | XB03BBY050A001010704781 | NHSA |
| 山东鑫惠药业有限公司 | 国药准字H20194058 | 0.4mg | Category A (甲) | XB03BBY050A001010780465 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001010783521 | NHSA |
| 北京斯利安药业有限公司 | 国药准字H10970079 | 0.4mg | Category A (甲) | XB03BBY050A001010800011 | NHSA |
| 烟台中洲制药有限公司 | 国药准字H20093829 | 0.4mg | Category A (甲) | XB03BBY050A001010804253 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19993229 | 0.4mg | Category A (甲) | XB03BBY050A001010804781 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001010883521 | NHSA |
| 北京斯利安药业有限公司 | 国药准字H10970079 | 0.4mg | Category A (甲) | XB03BBY050A001010900011 | NHSA |
| 烟台中洲制药有限公司 | 国药准字H20093829 | 0.4mg | Category A (甲) | XB03BBY050A001010904253 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19993229 | 0.4mg | Category A (甲) | XB03BBY050A001010904781 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001010983521 | NHSA |
| 北京斯利安药业有限公司 | 国药准字H10970079 | 0.4mg | Category A (甲) | XB03BBY050A001011000011 | NHSA |
| 烟台中洲制药有限公司 | 国药准字H20093829 | 0.4mg | Category A (甲) | XB03BBY050A001011004253 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001011083521 | NHSA |
| 北京斯利安药业有限公司 | 国药准字H10970079 | 0.4mg | Category A (甲) | XB03BBY050A001011100011 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19993229 | 0.4mg | Category A (甲) | XB03BBY050A001011104781 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001011183521 | NHSA |
| 北京斯利安药业有限公司 | 国药准字H10970079 | 0.4mg | Category A (甲) | XB03BBY050A001011200011 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19993229 | 0.4mg | Category A (甲) | XB03BBY050A001011204781 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001011283521 | NHSA |
| 北京斯利安药业有限公司 | 国药准字H10970079 | 0.4mg | Category A (甲) | XB03BBY050A001011300011 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001011383521 | NHSA |
| 北京斯利安药业有限公司 | 国药准字H10970079 | 0.4mg | Category A (甲) | XB03BBY050A001011400011 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001011483521 | NHSA |
| 北京斯利安药业有限公司 | 国药准字H10970079 | 0.4mg | Category A (甲) | XB03BBY050A001011500011 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001011583521 | NHSA |
| 北京斯利安药业有限公司 | 国药准字H10970079 | 0.4mg | Category A (甲) | XB03BBY050A001011600011 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001011683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001011783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001011883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001011983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001012083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001012183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001012283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001012383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001012483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001012583521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001012683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001012783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001012883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001012983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001013083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001013183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001013283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001013383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001013483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001013583521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001013683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001013783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001013883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20244242 | 5mg | Category A (甲) | XB03BBY050A001013983521 | NHSA |
| 华润紫竹药业有限公司 | 国药准字H20183478 | 0.4mg | Category A (甲) | XB03BBY050A001020100225 | NHSA |
| 秦皇岛爱晖药业有限公司 | 国药准字H12020597 | 5mg | Category A (甲) | XB03BBY050A001020100858 | NHSA |
| 天津力生制药股份有限公司 | 国药准字H12020215 | 5mg | Category A (甲) | XB03BBY050A001020100886 | NHSA |
| 常州制药厂有限公司 | 国药准字H32023302 | 5mg | Category A (甲) | XB03BBY050A001020101397 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20044918 | 5mg | Category A (甲) | XB03BBY050A001020101467 | NHSA |
| 华北制药股份有限公司 | 国药准字H20143386 | 0.4mg | Category A (甲) | XB03BBY050A001020102690 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19993229 | 0.4mg | Category A (甲) | XB03BBY050A001020104781 | NHSA |
| 江西制药有限责任公司 | 国药准字H36020872 | 0.4毫克 | Category A (甲) | XB03BBY050A001020105388 | NHSA |
| 华润紫竹药业有限公司 | 国药准字H20183478 | 0.4mg | Category A (甲) | XB03BBY050A001020200225 | NHSA |
| 常州制药厂有限公司 | 国药准字H32023302 | 5mg | Category A (甲) | XB03BBY050A001020201397 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20044918 | 5mg | Category A (甲) | XB03BBY050A001020201467 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19993229 | 0.4mg | Category A (甲) | XB03BBY050A001020204781 | NHSA |
| 常州制药厂有限公司 | 国药准字H32023302 | 5mg | Category A (甲) | XB03BBY050A001020301397 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19993229 | 0.4mg | Category A (甲) | XB03BBY050A001021304781 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19993229 | 0.4mg | Category A (甲) | XB03BBY050A001021404781 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19993229 | 0.4mg | Category A (甲) | XB03BBY050A001021504781 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19983051 | 5mg | Category A (甲) | XB03BBY050A001030104781 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19983051 | 5mg | Category A (甲) | XB03BBY050A001030204781 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19983051 | 5mg | Category A (甲) | XB03BBY050A001030304781 | NHSA |
| 厦门宝华生物制药有限公司 | 国药准字H19983051 | 5mg | Category A (甲) | XB03BBY050A001030404781 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 12 filings and 12 distinct first applicants.
Generic 10 · Supplement 2
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 浙江诺得药业有限公司 | CYHS2200209 | Generic | 2022/01/27 | Not stated by source | CDE |
| 江苏迪赛诺制药有限公司 | CYHS2602286 | Generic | 2026/09/15 | Not stated by source | CDE |
| 北京恒生药业有限公司 | CYHS2602096 | Generic | 2026/08/24 | Not stated by source | CDE |
| 石药集团欧意药业有限公司 | CYHB2650046 | Supplement | 2026/02/07 | Not stated by source | CDE |
| 福州海王福药制药有限公司 | CYHB2550404 | Supplement | 2025/12/18 | Not stated by source | CDE |
| 北京福元医药股份有限公司 | CYHS2504043 | Generic | 2025/11/24 | Not stated by source | CDE |
| 建昌帮药业有限公司;北京斯利安药业有限公司 | CYHS2502979 | Generic | 2025/08/14 | Not stated by source | CDE |
| 成都通德药业有限公司 | CYHS2502973 | Generic | 2025/08/14 | Not stated by source | CDE |
| 赤峰固得药业有限公司;湖南九典制药股份有限公司 | CYHS2502288 | Generic | 2025/06/26 | Not stated by source | CDE |
| 安徽圣鹰药业有限公司 | CYHS2501789 | Generic | 2025/05/17 | Not stated by source | CDE |
| 广州朗圣药业有限公司 | CYHS2200810 | Generic | 2022/06/01 | Not stated by source | CDE |
| 昆明源瑞制药有限公司 | CYHS2602725 | Generic | 2026/11/06 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 3 filings and 3 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏迪赛诺制药有限公司 | CYHS2602286 | Generic | 2026/09/15 | Not stated by source | CDE |
| 北京恒生药业有限公司 | CYHS2602096 | Generic | 2026/08/24 | Not stated by source | CDE |
| 昆明源瑞制药有限公司 | CYHS2602725 | Generic | 2026/11/06 | Not stated by source | CDE |
API registrations
Non-component matches: 8 companies with A status and 2 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 叶酸 | 江西天新药业股份有限公司 | Y20220000258 | A | Exact ingredient | 2025/01/18 | CDE |
| 叶酸 | 山东鲁盛制药有限公司 | Y20210001277 | I | Exact ingredient | 2022/11/16 | CDE |
| 叶酸 | 浙江圣达生物药业股份有限公司 | Y20190021595 | A | Exact ingredient | 2024/09/15 | CDE |
| 叶酸 | 河北冀衡药业股份有限公司 | Y20190009613 | A | Exact ingredient | 2025/06/19 | CDE |
| 叶酸 | dsm-firmenich Switzerland AG | Y20190009042 | A | Exact ingredient | 2025/12/10 | CDE |
| 叶酸 | 常州制药厂有限公司 | Y20190008583 | A | Exact ingredient | 2025/06/21 | CDE |
| 叶酸 | 江苏联环药业股份有限公司 | Y20190006371 | A | Exact ingredient | — | CDE |
| 叶酸 | 北京斯利安药业有限公司 | Y20190006007 | A | Exact ingredient | 2023/03/24 | CDE |
| 叶酸 | 常州亚邦制药有限公司 | Y20190004959 | A | Exact ingredient | 2025/09/29 | CDE |
| 叶酸 | 河北冀衡（集团）药业有限公司 | Y20180001306 | I | Exact ingredient | 2018/11/30 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/06No longer listed under review
江苏亚邦爱普森药业有限公司
CYHB2550259
Fact date: 2026/11/06 · Site observation date: 2026/11/06
Accepted: 2025/07/16
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/11/06 (approval no.: —; approval date: 2026/11/03); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 8
NMPA · Table row 8 ↗ View source ↗ -
2026/11/06Accepted
-
2026/11/03Supplement delivery
江苏亚邦爱普森药业有限公司
CYHB2550259
Fact date: 2026/11/03 · Publication date: 2026/11/06 · Site observation date: 2026/11/06
Supplemental application; excluded from new marketing approvals.
View source · Table row 8 ↗ -
2026/09/15Accepted
-
2026/08/24Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Folic Acid Tablets
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy